Study summary
Risankizumab tripled remission at induction and kept most responders in remission for a year
20.3%in remission at 12 weeks, vs 6.2% with placebo
What was tested
Risankizumab, another IL-23 blocker, against placebo, for induction and then maintenance of ulcerative colitis.
What they found
- Induction remission was 20.3% vs 6.2%.
- At 1 year of maintenance, remission was about 40% vs 25% with placebo.
What it means
A second IL-23 option, already approved for Crohn's disease.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.